Variable | Mean (SD) or frequency (%) |
Age (years) | 47.7 (13.7) |
Sex: female (%) | 66 (49%) |
PsA duration (years) | 4.7 (6.8) |
No. of prior DMARDs (%) | |
0 | 52 (38.5%) |
1 | 33 (24.5%) |
2+ | 50 (37%) |
No. of prior b/tsDMARD (%) | |
0 | 90 (66.7%) |
1 | 19 (14.1%) |
2 | 13 (9.6%) |
3+ | 13 (9.6%) |
Tender joints (0–68) | 6.5 (5.5) |
Swollen joints (0–66) | 4.7 (4.6) |
Enthesitis (any) | 81 (60%) |
SPARCC | 1.6 (1.7) |
Dactylitis (any) | 39 (28.9%) |
Dactylitis count | 0.5 (0.9) |
PASI | 4.5 (5.6) |
hsCRP | 7.6 (11.8) |
DAPSA | 29.1 (18.8) |
Pain (0–10) | 5.1 (2.4) |
Patient global (0–10) | 5.2 (2.4) |
Physician global (0–10) | 5.1 (1.7) |
HAQ (0–3) | 0.7 (0.5) |
Medications analysed for treatment outcomes | ||
DAPSA change (n=87) | Drug persistence (n=105) | |
csDMARD | 11 | 13 |
Methotrexate | 9 | 11 |
Sulfasalazine | 2 | 2 |
Start ts/bDMARD* | ||
TNF inhibitor | 41 | 44 |
IL-17 inhibitor | 28 | 37 |
IL12/23 or IL-23 inhibitor | 1 | 1 |
JAK inhibitor | 6 | 10 |
b/tsDMARD, biologic and targeted Disease-modifying antirheumatic drugs; csDMARD, conventional synthetic DMARD; DAPSA, Disease Activity Index for Psoriatic Arthritis; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire for rheumatoid arthritis; hsCRP, high-sensitivity C reactive protein; IL, Interleukin (IL); JAK, Janus Kinase; PASI, Psoriasis Area and Severity Index; SPARCC, Spondyloarthritis Research Consortium of Canada; TNF, Tumor Necrosis Factor.